Overview
Erasca reports Q3 net loss of $30.6 mln, similar to last year
R&D expenses decreased to $22.5 mln from $27.6 mln year-over-year
Company's cash position of $362 mln expected to fund operations into H2 2028
Outlook
Company expects initial Phase 1 data for ERAS-0015 and ERAS-4001 in 2026
Erasca's cash reserves expected to fund operations into H2 2028
Result Drivers
PATENT ISSUANCE - U.S. patent issued for pan-RAS molecular glue ERAS-0015, strengthening intellectual property portfolio
LEADERSHIP PROMOTION - Robert Shoemaker, Ph.D., promoted to chief scientific officer, reinforcing scientific leadership
R&D expenses were $22.5 million for the quarter ended September 30, 2025, compared to $27.6 million for the quarter ended September 30, 2024.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$30.61 mln | ||
Q3 Basic EPS | -$0.11 | ||
Q3 Operating Expenses | $34.55 mln | ||
Q3 Operating Income | -$34.55 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Erasca Inc is $4.00, about 41% above its November 11 closing price of $2.36
Press Release: ID:nGNX9GvYyv
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)